

April 18, 2008

To Whom It May Concern

KYORIN Co., Ltd.
5, Kanda Surugadai 2-chome,
Chiyoda-ku, Tokyo
Securities Code: 4569; TSE 1st Section

LAUNCH OF "KIPRES[®] TABLETS 5MG"

KYORIN Co., Ltd. announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd. (Headquarter: Tokyo, President: Ikuo Ogihara) launched today "Kipres[®] Tablets 5mg" (INN: montelukast sodium), a leukotriene receptor antagonist / bronchial asthma and allergic rhinitis treatment drug, which was already approved on January 25, 2008.

Montelukast sodium has been developed by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. KYORIN Pharmaceutical has been contributing to the asthma treatment through marketing products containing montelukast sodium, "Kipres[®] Tablets 10mg" for adults and "Kipres[®] Chewable Tablets 5mg" for pediatric patients aged 6 years and older, since August 2001, and "Kipres[®] Oral Granules 4mg" for pediatric patients aged 1 year and older but under 6 years since October 2007. In addition, the company has obtained a marketing approval of allergic rhinitis in adults for "Kipres[®] Tablets 10mg" in January 2008.

Treatment by the daily single dose (bed time) of "Kipres[®] Tablets 5mg" has demonstrated its efficacy and safety profiles comparable to those of "Kipres[®] Tablets 10mg" in adult allergic rhinitis and improved three major symptoms of allergic rhinitis; stuffy nose, runny nose and sneezing. This product has approval for the treatment of bronchial asthma in adults while approved dose (dosage for bronchial asthma in adults is 10mg).

KYORIN Pharmaceutical has been pursuing Franchise Customers Strategy under which the company has been concentrating its marketing resources on the fields of respiratory, ear nose throat (ENT) and urology. The company will continue to make efforts to further contribute to asthma and allergic rhinitis treatments through aiming to immediately penetrate Kipres into the markets of respiratory and ENT.

###

Contacts: Management Planning Department KYORIN Co., Ltd. TEL: 3-3293-3414

<Products Profile>

1. Brand Name	Kipres [®] Tablets 5mg	Kipres [®] Tablets 10mg
2. Nonproprietary Name	Montelukast Sodium	
3. Indications	Bronchial Asthma, Allergic Rhinitis	
4. Dosage and Administration	<p>< Bronchial Asthma > Recommended dosage for adults is usually 10mg as montelukast orally administered once daily before bedtime.</p> <p>< Allergic Rhinitis > Recommended dosage for adults is usually 5-10mg as montelukast orally administered once daily before bedtime.</p>	
5. NHI Price	JPY 272.20 per tablet	JPY 199.70 per tablet
6. Packaging	PTP 28, 100, 140, and 420 tablets	PTP 28, 100, and 140 tablets

Reference

1. Brand Name	Kipres [®] Oral Granules 4mg	Kipres [®] Chewable 5mg
2. Indications	Bronchial Asthma	
3. Dosage and Administration	Recommended dosage for pediatric patients aged 1 year or older but under 6 years is usually 4mg (1 packet) as montelukast orally administered once daily before bedtime.	Recommended dosage for pediatric patients aged 6 years or older is usually 5mg as montelukast orally administered once daily before bedtime.
4. NHI Price	JPY 262.20 per packet	JPY 255.60 per tablet
5. Packaging	Aluminum Packet 28, 100, and 140 packets	PTP 28 and 100 tablets